CPC C07K 16/2803 (2013.01) [A61K 39/0011 (2013.01); C07K 16/3061 (2013.01); C12N 5/0638 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/74 (2013.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); C12N 15/625 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01); C12N 2501/505 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01)] | 26 Claims |
1. A method of treating a hematological cancer that expresses CD22 in a human, the method comprising administering to the human an effective amount of a chimeric antigen receptor (CAR) T cell to treat the hematological cancer that expresses CD22 in the human; wherein the CAR comprises (a) an antigen binding domain of an antibody which binds to CD22, (b) a transmembrane domain, and (c) an intracellular T cell signaling domain,
wherein the antigen binding domain comprises an amino acid sequence comprising a heavy chain CDR1 comprising SEQ ID NO: 1, a heavy chain CDR2 comprising SEQ ID NO: 2, a heavy chain CDR3 comprising SEQ ID NO: 3, a light chain CDR1 comprising SEQ ID NO: 4, a light chain CDR2 comprising SEQ ID NO: 5, and a light chain CDR3 comprising SEQ ID NO: 6, and
wherein the CAR is the sole CAR expressed by the T cell.
|